Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Lumateperone LAI in Schizophrenia
NCT04709224Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumateperone in schizophrenia (4 arms), sponsored by Intra-Cellular Therapies. Primary endpoints: Maximum observed plasma concentration, Time of maximum observed plasma concentration and 9 more. Started Dec 2020; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04709224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709224.